STOCK TITAN

Akebia Therapeutics, Inc. - $AKBA STOCK NEWS

Welcome to our dedicated page for Akebia Therapeutics news (Ticker: $AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Akebia Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Akebia Therapeutics's position in the market.

Rhea-AI Summary
Akebia Therapeutics announces FDA acknowledgment of complete resubmission for vadadustat as a treatment for anemia due to chronic kidney disease. FDA sets user fee goal date for March 27, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.65%
Tags
-
Rhea-AI Summary
Akebia Therapeutics to present data at ASN Kidney Week 2023, including alternate dosing for vadadustat in the treatment of anemia due to chronic kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics granted options to purchase 2,000 shares of common stock to a newly-hired employee. The options have an exercise price of $1.14 per share and vest over four years. Each option has a 10-year term.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
Rhea-AI Summary
Akebia Therapeutics has resubmitted its New Drug Application to the FDA for vadadustat, an oral treatment for anemia due to chronic kidney disease. The resubmission includes post-marketing safety data from Japan. A letter from the FDA acknowledging the resubmission is expected in 30 days, with a PDUFA date set for six months from submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics receives approval for Vafseo in Australia for the treatment of anemia in CKD patients on dialysis. Vadadustat achieved primary and secondary efficacy endpoints in clinical trials. Akebia plans to resubmit new drug application for vadadustat in the US. Akebia appoints Graham Ray as VP to lead customer engagement. Auryxia net product revenue guidance slightly lowered to $170-$175 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. The conference will be held in New York from September 11-13, 2023. The webcast of the presentation can be accessed through Akebia's website, with a replay available for approximately 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
Rhea-AI Summary
Akebia Therapeutics grants options to newly-hired employees as inducements
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary
Akebia reports Q2 2023 net product revenue of $42.2 million for Auryxia and reaffirms 2023 revenue guidance of $175.0-$180.0 million. Plans to resubmit NDA for vadadustat in Q3 2023. Akebia gains approval for vadadustat in 33 additional countries. Akebia enters exclusive license agreement with Medice. Net loss of $11.2 million for Q2 2023. Cash position of $53.6 million as of June 30, 2023. Akebia identifies accounting errors and material weakness in internal controls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Akebia expects to resubmit NDA for vadadustat by Q3 2023, received productive meeting minutes with FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
Rhea-AI Summary
Akebia to release Q2 financial results on August 25th and host conference call at 9:00 a.m. ET
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences earnings
Akebia Therapeutics, Inc.

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

236.84M
188.22M
2.47%
26.27%
6.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CAMBRIDGE

About AKBA

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.